272 related articles for article (PubMed ID: 31383961)
1. "Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.
Torlakovic E; Lim HJ; Adam J; Barnes P; Bigras G; Chan AWH; Cheung CC; Chung JH; Couture C; Fiset PO; Fujimoto D; Han G; Hirsch FR; Ilie M; Ionescu D; Li C; Munari E; Okuda K; Ratcliffe MJ; Rimm DL; Ross C; Røge R; Scheel AH; Soo RA; Swanson PE; Tretiakova M; To KF; Vainer GW; Wang H; Xu Z; Zielinski D; Tsao MS
Mod Pathol; 2020 Jan; 33(1):4-17. PubMed ID: 31383961
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.
Koomen BM; Badrising SK; van den Heuvel MM; Willems SM
Histopathology; 2020 May; 76(6):793-802. PubMed ID: 31793055
[TBL] [Abstract][Full Text] [Related]
4. Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Huang X; Ding Q; Guo H; Gong Y; Zhao J; Zhao M; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Hum Pathol; 2021 Feb; 108():42-50. PubMed ID: 33221342
[TBL] [Abstract][Full Text] [Related]
5. Digital quantitative assessment of PD-L1 using digital spatial profiling.
Gupta S; Zugazagoitia J; Martinez-Morilla S; Fuhrman K; Rimm DL
Lab Invest; 2020 Oct; 100(10):1311-1317. PubMed ID: 32249818
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
Ahn S; Kim KM
Mod Pathol; 2021 Sep; 34(9):1719-1727. PubMed ID: 34002009
[TBL] [Abstract][Full Text] [Related]
7. Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review.
Prince EA; Sanzari JK; Pandya D; Huron D; Edwards R
JCO Precis Oncol; 2021 Jun; 5():953-973. PubMed ID: 34136742
[TBL] [Abstract][Full Text] [Related]
8. Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.
Koppel C; Schwellenbach H; Zielinski D; Eckstein S; Martin-Ortega M; D'Arrigo C; Schildhaus HU; Rüschoff J; Jasani B
Mod Pathol; 2018 Nov; 31(11):1630-1644. PubMed ID: 29946185
[TBL] [Abstract][Full Text] [Related]
9. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
[TBL] [Abstract][Full Text] [Related]
10. [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].
Lantuejoul S; Adam J; Girard N; Duruisseaux M; Mansuet-Lupo A; Cazes A; Rouquette I; Gibault L; Garcia S; Antoine M; Vignaud JM; Galateau-Sallé F; Sagan C; Badoual C; Penault-Llorca F; Damotte D;
Ann Pathol; 2018 Apr; 38(2):110-125. PubMed ID: 29571563
[TBL] [Abstract][Full Text] [Related]
11. Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms.
Giunchi F; Gevaert T; Scarpelli M; Fiorentino M
Curr Drug Targets; 2020; 21(13):1286-1292. PubMed ID: 31971109
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
[TBL] [Abstract][Full Text] [Related]
13. A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma.
Shi L; Zhang SJ; Chen J; Lu SX; Fan XJ; Tong JH; Chow C; Tin EK; Chan SL; Chong CC; Lai PB; To KF; Wong N; Chan AW
Mod Pathol; 2019 Nov; 32(11):1646-1656. PubMed ID: 31231126
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.
Gevaert T; Cimadamore A; Montironi R; Eckstein M
Curr Drug Targets; 2021; 22(2):162-170. PubMed ID: 32386490
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
[TBL] [Abstract][Full Text] [Related]
16. Predictive potential and need for standardization of PD-L1 immunohistochemistry.
Savic Prince S; Bubendorf L
Virchows Arch; 2019 Apr; 474(4):475-484. PubMed ID: 30173280
[TBL] [Abstract][Full Text] [Related]
17. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare.
Zouein J; Kesrouani C; Kourie HR
Immunotherapy; 2021 Aug; 13(12):1053-1065. PubMed ID: 34190579
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Doroshow DB; Bhalla S; Beasley MB; Sholl LM; Kerr KM; Gnjatic S; Wistuba II; Rimm DL; Tsao MS; Hirsch FR
Nat Rev Clin Oncol; 2021 Jun; 18(6):345-362. PubMed ID: 33580222
[TBL] [Abstract][Full Text] [Related]
20. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
Maule JG; Clinton LK; Graf RP; Xiao J; Oxnard GR; Ross JS; Huang RSP
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]